Oncology Diagnostics Attracts Big Money

MORE SURPRISING DEVELOPMENTS for the anatomic pathology profession during the past three weeks! The impending $215 million acquisition of IMPATH, Inc. by Genzyme Corporation, announced on March 1, has the potential to send new ripples across the national market for oncology testing. What makes the Genzyme–IMPATH combination particularly fascinating was the $1 billion Genzyme paid, just …

Oncology Diagnostics Attracts Big Money Read More »

To access this post, you must purchase The Dark Report.

Oncology Diagnostics Attracts Big Money

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month